TLP
ARCT icon

Tri Locum Partners’s Arcturus Therapeutics ARCT Stock Holding History

Tri Locum Partners’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-138,927
Closed -$4.69M – 26
2024
Q1 		$4.69M Buy
138,927
+28,457
+26% +$1.01M 1.63% 23
2023
Q4 		$3.48M Sell
110,470
-98,416
-47% -$2.34M 1.59% 21
2023
Q3 		$5.34M Buy
+208,886
New +$6.43M 1.71% 19
2021
Q1 		– Sell
-26,722
Closed -$1.16M – 38
2020
Q4 		$1.16M Buy
+26,722
New +$1.81M 0.42% 34

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Tri Locum Partners's ARCT Position: Q2 2024 in Review

Tri Locum Partners sold out of Arcturus Therapeutics (ARCT) in Q2 2024, closing a stake of 138,927 shares — an estimated $4.69M sold.

Tri Locum Partners first reported a position in ARCT in Q4 2020 and held it in 4 quarters. The position peaked at $5.34M in Q3 2023. 171 funds tracked by Wall St. Rank hold ARCT as of Q2 2024.

  • Tri Locum Partners reported no remaining Arcturus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Tri Locum Partners sold 138,927 Arcturus Therapeutics shares in Q2 2024, an estimated $4.69M.
  • Tri Locum Partners first reported a position in Arcturus Therapeutics in Q4 2020 and held it in 4 quarters.
  • Tri Locum Partners's Arcturus Therapeutics position peaked at $5.34M in Q3 2023.
  • 171 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2024.

Based on Tri Locum Partners's 13F filing for Q2 2024, filed 14 Aug 2024.